NCT03587519

Brief Summary

In patients with ulcerative or indeterminate colitis who undergo ileal pouch anal anastomosis and diverting loop ileostomy (IPAA) surgery\* a short interval to loop ileostomy reversal will result in differences in complications and quality of life compared to a long interval to loop ileostomy reversal.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
36

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Nov 2018

Typical duration for not_applicable

Geographic Reach
1 country

8 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 26, 2018

Completed
20 days until next milestone

First Posted

Study publicly available on registry

July 16, 2018

Completed
4 months until next milestone

Study Start

First participant enrolled

November 6, 2018

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 16, 2021

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

March 31, 2021

Completed
Last Updated

March 4, 2022

Status Verified

February 1, 2022

Enrollment Period

2.3 years

First QC Date

June 26, 2018

Last Update Submit

February 8, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Comprehensive Complication Index at 6 months after randomization.

    The CCI® calculator is an online tool to support the assessment of patients' overall morbidity. The Comprehensive Complication Index (CCI®) is based on the complication grading by Clavien-Dindo Classification and implements every occurred complication after an intervention. The overall morbidity is reflected on a scale from 0 (no complication) to 100 (death).

    6 months

Secondary Outcomes (5)

  • Total number of postoperative complications per patient

    6 months

  • Percent of patients with complications

    1-2 month intervals after randomization through 6 months".

  • Total number of stoma related complications per patient

    1-2 month intervals after randomization through 6 months

  • Health-related quality of life

    Once, at 6 months after ostomy closure surgery

  • IPAA functional outcomes

    Once, at 6 months after ostomy closure surgery

Study Arms (2)

Early ileostomy closure

EXPERIMENTAL

Early ileostomy closure will be performed 7 to 12 days after with ileal j-pouch anal anastomosis (IPAA) and loop ileostomy (IPAA).

Procedure: Early

Late ileostomy closure

ACTIVE COMPARATOR

Late ileostomy closure will be performed 8 - 12 weeks after IPAA.

Procedure: Late

Interventions

EarlyPROCEDURE

Early ileostomy closure

Early ileostomy closure
LatePROCEDURE

Late ileostomy closure

Late ileostomy closure

Eligibility Criteria

Age18 Years - 64 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Signed informed consents.
  • Man or woman between 18 and 64 years of age.
  • Ulcerative colitis (UC) or indeterminate colitis (IC) diagnosed by routine clinical, radiographic, endoscopic, and pathological criteria.
  • Patient will be scheduled for non-emergent proctocolectomy or completion proctectomy with ileal j-pouch anal anastomosis (IPAA) and loop ileostomy (IPAA).
  • Clinical assessment of patient after IPAA surgery indicates that patient is suitable for early ileostomy reversal

You may not qualify if:

  • Age \< 18 or \> 64 years
  • Colon or rectal cancer
  • Crohn's disease or suspected Crohn's disease
  • Prednisone dose \> 20 mg per day (or equivalent other steroid dose) within 4 weeks of scheduled IPAA
  • Body mass index (BMI) equal to or greater than 40 kg/m2
  • Hemodynamic instability (persistent pulse rate \< 50 or \> 120 bpm, systolic blood pressure \< 90 or \> 160 mm Hg, uncontrolled cardiac arrhythmia, or active vasopressor drug use)
  • Organ transplant recipient (e.g. Liver, Kidney, Pancreas)
  • Immunosuppression due to chemotherapy drug use or systemic disease.
  • Sepsis
  • Renal insufficiency (i.e. serum creatinine ? 2 mg/dl or need for dialysis)
  • Therapeutic anticoagulation (e.g. venous thromboembolic disease, prosthetic heart valve)
  • Blood Hemoglobin \< 8 g/dl
  • Serum Albumin \< 2.5 g/dl
  • Individualized decision by the surgeon to exclude the patient based on sound surgical judgment
  • Pregnant patients and female patients who do not satisfy the standard of care requirements of participating centers for an elective surgical procedure.
  • +3 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (8)

Cedars Sinai

Los Angeles, California, 90048, United States

Location

University of Colorado Denver

Aurora, Colorado, 80045, United States

Location

Northwestern University Medical Center

Chicago, Illinois, 60611, United States

Location

University of Chicago

Chicago, Illinois, 60637, United States

Location

Beth Israel

Boston, Massachusetts, 02215, United States

Location

University of Michigan

Ann Arbor, Michigan, 48109, United States

Location

Washington University

St Louis, Missouri, 63110, United States

Location

Cleveland Clinic

Cleveland, Ohio, 44195, United States

Location

Related Publications (1)

  • Vogel JD, Fleshner PR, Holubar SD, Poylin VY, Regenbogen SE, Chapman BC, Messaris E, Mutch MG, Hyman NH. High Complication Rate After Early Ileostomy Closure: Early Termination of the Short Versus Long Interval to Loop Ileostomy Reversal After Pouch Surgery Randomized Trial. Dis Colon Rectum. 2023 Feb 1;66(2):253-261. doi: 10.1097/DCR.0000000000002427. Epub 2023 Jan 6.

MeSH Terms

Conditions

Colitis, Ulcerative

Condition Hierarchy (Ancestors)

ColitisGastroenteritisGastrointestinal DiseasesDigestive System DiseasesInflammatory Bowel DiseasesColonic DiseasesIntestinal Diseases

Study Officials

  • Jon Vogel, MD

    University of Colorado, Denver

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 26, 2018

First Posted

July 16, 2018

Study Start

November 6, 2018

Primary Completion

February 16, 2021

Study Completion

March 31, 2021

Last Updated

March 4, 2022

Record last verified: 2022-02

Locations